Patents Assigned to NovaTarg, Inc.
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11834411
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: December 5, 2023
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11261157
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 1, 2022
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares